2H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design-Reference-Cited by-同舟云学术

2H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design

Published:2018-03-29 Issue:8 Volume:61 Page:3370-3388
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Giroud Maude¹,Kuhn Bernd²,Saint-Auret Sarah²,Kuratli Christoph²,Martin Rainer E.²^ORCID,Schuler Franz²,Diederich François¹^ORCID,Kaiser Marcel³⁴,Brun Reto³⁴,Schirmeister Tanja⁵,Haap Wolfgang²^ORCID

Affiliation:

1. Laboratorium für Organische Chemie, ETH Zurich, Vladimir-Prelog-Weg 3, 8093 Zürich, Switzerland

2. Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland

3. Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051 Basel, Switzerland

4. University of Basel, Petersplatz 1, 4003 Basel, Switzerland

5. Institut für Pharmazie und Biochemie, Johannes Gutenberg-Universität Mainz, Staudinger Weg 5, 55128 Mainz, Germany

Funder

Eidgen?ssische Technische Hochschule Z?rich

Deutsche Forschungsgemeinschaft

F. Hoffmann-La Roche

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b01870

Reference74 articles.

1. Human African trypanosomiasis

2. Lejon, V.; Bentivoglio, M.; Franco, J. R. In Handbook of Clinical Neurology; Garcia, H. H., Tanowitz, H. B., Del Brutto, O. H., Eds. Elsevier B. V.: Amsterdam, The Netherlands, 2013; Chapter 11: Human African Trypanosomiasis, Vol. 114, pp 169–181.

3. Sleeping sickness

4. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial

5. Target Product Profile–Sleeping Sickness; Drugs for Neglected Diseases Initiative: Geneva, Switzerland. https://www.dndi.org/diseases-projects/hat/hat-target-product-profile/ (accessed January 15, 2017).

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Novel Peptidyl Nitriles Targeting Rhodesain and Falcipain-2 for the Treatment of Sleeping Sickness and Malaria;International Journal of Molecular Sciences;2024-04-17

2. Practical synthesis of 1-alkyl 5-methyl ester 1,2,3-triazoles from low boiling point azides;Tetrahedron Letters;2024-04

3. Exploring the latest breakthroughs in rhodesain inhibitors for African trypanosomiasis;Medicinal Chemistry Research;2024-02-02

4. Drug Discovery Efforts to Identify Novel Treatments for Neglected Tropical Diseases - Cysteine Protease Inhibitors;Current Medicinal Chemistry;2023-11-01

5. Influence of amino acid size at the P3 position of N-Cbz-tripeptide Michael acceptors targeting falcipain-2 and rhodesain for the treatment of malaria and human african trypanosomiasis;Bioorganic Chemistry;2023-08